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Since the discovery of induced pluripotent stem cells (iPSC) in 2006, the symptoms of many human diseases have
been reversed in animal models with iPSC therapy, setting the stage for future clinical development. From the
animal data it is clear that iPSC are rapidly becoming the lead cell type for cell replacement therapy and for the
newly developing field of iPSC-derived body organ transplantation. The first human pathology that might be
treated in the near future with iPSC is age-related macular degeneration (AMD), which has recently passed the
criteria set down by regulators for phase I clinical trials with allogeneic human embryonic stem cell-derived cell
transplantation in humans. Given that iPSC are currently in clinical trial in Japan (RIKEN) to treat AMD, the establishment
of a set of international criteria to make clinical-grade iPSC and their differentiated progeny is the next step in order to
prepare for future autologous cell therapy clinical trials. Armed with clinical-grade iPSC, we can then specifically test for
their threat of cancer, for proper and efficient differentiation to the correct cell type to treat human disease and then to
determine their immunogenicity. Such a rigorous approach sets a far more relevant paradigm for their intended future
use than non-clinical-grade iPSC. This review focuses on the latest developments regarding the first possible use of
iPSC-derived retinal pigment epithelial cells in treating human disease, covers data gathered on animal models to date
and methods to make clinical-grade iPSC, suggests techniques to ensure quality control and discusses possible clinical
immune responses.Review
iPSC to treat animal models of human disease
Many human diseases have been successfully ‘treated’ in
animal models with induced pluripotent stem cells
(iPSC) or human embryonic stem cell (hESC)-derived
cells, such as sickle cell anaemia [1] (blood cell replace-
ment), amyotrophic lateral sclerosis (ALS) [2-4] (motor
neuron cell replacement), age-related macular degener-
ation (AMD) [5-7] (retinal pigment epithelial (RPE)
cells), spinal cord injury [8-10] (neural stem cells) and
Parkinson’s disease [11-13] (dopaminergic neuron re-
placement), providing essential in vivo pre-clinical data.
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article, unless otherwise stated.animal data to provide a solid platform to move towards
clinical trials in the near future. This review focuses on
the latest developments regarding the first possible use
of iPSC-derived retinal pigment epithelial cells in treat-
ing human macular degeneration.Rat model for macular degeneration
Many different animal models have been used to test
RPE cell function in vivo [14,15]. The Royal College of
Surgeons (RCS) rat is an animal model of retinal pig-
ment epithelium dystrophy that has been used exten-
sively to demonstrate the proof of principle and
mechanism of visual rescue in RPE transplantation. This
dystrophic strain of rat has a recessive mutation in the
MerTK gene that results in failure of RPE cells to phago-
cytose rod outer segments [16-18]. The consequences of
this mutation include accumulation of subretinal debris,
death of rod photoreceptor cells and later cone cells,
secondary inner retinal degeneration, retinal vascularCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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circuitry.
Retinal degeneration in the RCS rat can be prevented
or reversed by subretinal transplantation of RPE cells
from a non-dystrophic congenic strain [19,20]. The RCS
rat has been used by a number of groups to examine dif-
ferent potential cell sources for RPE replacement for the
treatment of AMD and other retinal diseases (reviewed
by Carr et al. 2013) [21], including human foetal and
neonatal RPE [22,23], adult human RPE cell lines, such
as ARPE19 [24-26], stem cell-derived RPE from hESC
[5,27,28] and iPSC [6]. In all of these studies, trans-
planted RPE cells resulted in the preservation of the
photoreceptor layer, demonstrating the feasibility of
treating RPE dystrophy with cell therapy.
Interestingly, transplantation of neurospheres derived
from the human foetal forebrain into the RCS rat retina
was shown to rescue retinal degeneration in the absence
of RPE cell differentiation. Transplanted human neural
stem cells were shown to persist in the host for up to
4 months after transplantation and exhibited phagocytic
activity, resulting in the clearance of subretinal debris
and preservation of photoreceptor cells and retinal hist-
ology [29]. These observations suggest that neural stem
cells provide neurotrophic support to the retina; how-
ever, the uptake of subretinal debris by transplanted cells
suggests that additional functions such as phagocytic
clearance may be engaged in transplanted cells.
Transplantation of healthy RPE into the submacular
space has shown promising potential as a cure for AMD
and could offer an alternative to regular intraocular
injections of vascular endothelial growth factor (VEGF)
blocking drugs. Current surgical approaches to recon-
struct RPE in wet and dry AMD include full macular
translocation [30,31], which involves repositioning the
retina over a new patch of healthy RPE, and autologous
RPE-choroid patch grafting [32], which involves har-
vesting healthy RPE from peripheral retina. Short- and
long-term outcomes of translocation surgery in wet
AMD have provided proof of principal that visual func-
tion can be rescued by RPE transplantation [33,34].
However, there are significant limitations in these au-
tologous techniques related to surgical complications
[33]. Given these limitations, considerable effort has
been invested in the development of a simplified surgi-
cal approach that utilises a pre-made RPE patch for ret-
inal transplantation.
Methods to make clinical-grade iPSC
The generation of clinical-grade human iPSC (hiPSC)
should take into consideration several aspects of safety
and applicability, namely genome integrity, avoiding the
use of oncogenes, the use of xeno-free materials and
good manufacturing practices, high efficiency andpractical considerations to create a widely used cell
therapy approach.
Reprogramming without leaving traces in the genome
Since Yamanaka’s method to make iPSC, using retrovirus
for Oct4, Sox2, Klf4 and c-Myc genes, a reprogramming
method that does not leave permanent modifications of
the genome has been sought [35]. Different groups have
developed protocols to induce iPSC lines using excisable
lentiviral [36], transposon [37] or non-integrating epi-
somal vectors [38].
To avoid any remote risk of changes in the genome,
DNA-free methods have also been designed. Warren
and colleagues [39] were the first to show the induction
of iPSC from primary human fibroblast cultures by using
in vitro transcribed mRNA of the four classic repro-
gramming factors described by Yamanaka. Other groups
have also achieved reprogramming by methods such as
direct transfection of recombinant cell-penetrating re-
programming proteins in primary mouse embryo fibro-
blasts [40] or a combination of chemicals [41]. Methods
do exist to use xeno-free, virus-free, c-Myc-free and
feeder-free methods to make iPSC [42,43]. We are
adapting published methods [39,44,45] to develop a new
protocol for clinical-grade iPSC from human cord blood
stem cells and xeno-free human fibroblasts. The next
challenge will be to establish internationally accepted
guidelines to determine the quality of iPSC.
Xeno-free and good manufacturing procedures
To create iPSC lines and derivatives that are acceptable
for clinical use, it is necessary to use reagents for cell
culture, surface attachment and cell passage that are
chemically defined and free of any contamination of che-
micals that cause an immune response. Feeder-free cell
culture systems have been generated that can be adopted
for clinical use [46]. In these conditions, cell reprogram-
ming is accomplished without a feeder layer by plating
cells on vitronectin, allowing for controlled and reprodu-
cible conditions. Defined xeno-free media as well as at-
tachment and passaging reagents are now commercially
available from different manufacturers.
Another important aspect in the creation of clinical-
grade iPSC is to identify and follow good manufacturing
practices (GMP) for all processing steps. The production
of iPSC from skin biopsies entirely following GMP pro-
tocols have been generated following standard operating
procedures (SOP) [47] for each of the methods involved
in the generation and characterisation of iPSC lines [48].
They have classified SOP in five broad categories: ad-
ministrative, material management, equipment, manu-
facturing and quality control and assurance. However, to
date, SOP have only been described for retrovirally gen-
erated iPSC, and specific SOPs will need to be made for
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dards for the clinical use of iPSC are still to be defined,
and they will have to assess aspects such as genetic sta-
bility, safety, purity and identity.
High efficiency
High efficiency is a critical feature of any reprogram-
ming protocol that is suitable for the creation of clinical-
grade iPSC from patient cells. The addition of chemical
inhibitors of, for example, the p38 pathway, inositol
trisphosphate 3-kinase, Aurora A kinase and TGF-β re-
ceptor, has been shown to increase significantly the effi-
ciency of the reprogramming process [49]. Also, it has
been shown that depletion of nuclear protein mbd3 un-
blocks Oct4 and Sox2 promoters for activation, leading
not only to a dramatic increase in efficiency but also to a
considerable reduction in the reprogramming time com-
pared to standard reprogramming protocols [50].
Leaving out the oncogenes
One critical aspect in reprogramming cells to pluripo-
tency is the increased oncogenic potential of cells as a
result of genetic manipulation. This is of special concern
when introducing oncogenes such as Klf4 and particu-
larly c-Myc. Although it is possible to use repro-
gramming cocktails without c-Myc, the efficiency is
dramatically decreased [51]. In many cell types, c-Myc is
only transiently expressed in reprogramming protocols
and is a powerful oncogene able to induce cancer and
gene amplification [51,52]. We are trying to dissect cell
cycle effects of c-Myc, necessary for the reprogramming
process, from the undesirable tumorigenic effects by in-
vestigating the use of other cell cycle-related genes with
the aim of identifying a safe substitute for c-Myc [43].
Other genes, such as the translation enhancer lin28 or
chromatin modifying factors, have been used as an alter-
native approach to substitute potential oncogenes when
reprogramming [53].
iPSC bank from compatible donors
One of the attractive features of iPSC technology is the
possibility of creating autologous cell therapies using a
patient’s adult cells as a donor source, avoiding the im-
munological reactions likely to grafted non-autologous
cells. However, the personalised production of iPSC for
cell therapy would certainly be a costly and lengthy ap-
proach. The use of iPSC from immunologically compat-
ible donors would allow the creation of cell banks with
ready-to-use iPSC and derivatives that could be trans-
planted in a short time and with minimal rejection [54].
It has been estimated that ten cell lines homozygous for
common HLA antigens (HLA-A, HLA-B, HLA-DR)
would match 37% of the UK population and be benefi-
cial to 67% [55]. Efforts in Europe are currently beingmade to bring together national blood banks to collect
enough homozygous cord blood units to match a signifi-
cant percentage of the population.
Methods to evaluate the quality of iPSC
The question of iPSC quality depends on the classifica-
tion or definition of what we mean by the pluripotent
state of cells. Currently, we are aware of at least two
states for pluripotent stem cells, naive and primed [56],
and often cultures of ESC and iPSC exhibit characteris-
tics of both [57]. Some culture conditions may even pro-
mote reversion of iPSC to a totipotent state [58]. The
criteria for defining the respective stages of pluripotency
could include:
1. X chromosome inactivation state - female naive
cells harbour two active X chromosomes, while
primed cells possess one inactive X. This can be
assayed by analysing XIST transcription, a non-coding
RNA that initiates coding of one copy of the X
chromosome leading to its inactivation in primed
cells [56], and by analysing lysine 27 tri-methylation
modification of histone 3 (H3K27me3) on the X
chromosome [59].
2. Bivalent domain occupancy consisting of H3K27me3
and H3K4me3 modifications in the promoters
and bodies of developmental genes, respectively,
is more abundant in primed cells relative to naive
cells [60]. This has been proposed to contribute to
transcriptional induction of developmental genes
when iPSC are promoted to differentiate [61].
3. Activation of specific signalling cascades - TGF-β in
response to activin and receptor tyrosine kinase in
response to FGF in primed miPSC and hiPSC [62] and
inactivation of Erk signalling (or bypass stimulation by
LIF [63]) in naive miPSC and hiPSC [56]. Typical
cultures of hiPSC are thought to exhibit characteristics
of the primed state.
These parameters potentially lay the foundation for
the testing of pluripotency of iPSC clones, typically
following ten passages. To qualify as undifferentiated
hiPSC, clones are typically analysed to meet the follow-
ing criteria:
1. Self-renewal as compact flat colonies in the presence
of media supplemented with basic FGF and activin
A (or TGF-β).
2. Expression of core pluripotency factors, including
(but not limited to) OCT4, SOX2, NANOG (and
LIN28 on occasions) on the transcriptional and
protein levels, and alkaline phosphatase activity.
3. High histone bivalent domain occupancy (tested
infrequently) [57].
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are then further tested to analyse their ability to give rise
to progeny of the three germ layers. Classical tests include
differentiation tests in vitro and in vivo [64]:
1. Typical in vitro-based assays rely on treatment of
clones by media containing growth factors that
promote cell specification, for example, activin A,
BMP4 and Wnt3a, in the presence or absence of
FBS without basic FGF. Within 4 to 6 days, the cells
are tested for gene and protein expression in
embryonic lineages, including the classical markers
Pax6, Brachyury and Sox17 (ectoderm, mesoderm
and endoderm embryonic tissues, respectively).
Depending on the concentrations of the factors and
analysis time points, differentiated hiPSC should
present these markers [65].
2. The teratoma assay tests the capacity of hundreds
of thousands of transplanted cells to give rise to
teratoma tumours in immunodeficient mice. Many
host locations have been tested, among which the
most popular are subcutaneous injection and
kidney capsule engraftment. Clones that give rise
to benign tumours consisting of cells from the
three germ layers, represented typically by neural
rosettes, cartilage and gastrointestinal-like epithelium
(ectoderm, mesoderm and endoderm, respectively),
are considered pluripotent [64].
Assessing genetic aberrations is an additional import-
ant factor for determining the quality of hiPSC. Such
aberrations can result from cellular stress that accom-
panies reprogramming [66], selection during clone
propagation and from aberrations in the original somatic
cells. Characterisation assays typically rely on analysis of
gross chromosome (cytogenetic) integrity. Giemsa stain-
ing is an inexpensive technique that provides resolution
of several megabases. Considerably more expensive tech-
niques are fluorescent in situ hybridization (FISH)-based
and comparative genomic hybridization (CGH) assays
that can identify abnormalities up to the level of individ-
ual genes. Genomic approaches that are based on micro-
arrays and next-generation sequencing (NGS) are also
becoming popular for genomic characterisation of
hiPSC, and it is expected that, as prices go down and
analysis tools improve, they will become the standard,
replacing the cytogenetic tests [67]. However, the intro-
duction of genomic approaches makes it easier to detect
mutations and consequently it becomes more difficult to
decide on the definitions of hiPSC quality. Clones bear-
ing aberrations spanning thousands of base pairs are
generally regarded as poor quality, but quality assess-
ment of clones bearing several mutations is much more
complicated since it is difficult in many cases to assessthe influence of subtle mutations on cellular behaviour
and, similarly, it is difficult to assess the functional rele-
vance of SNPs [68]. Importantly, current genomic ap-
proaches cannot replace cytogenetic tests since the latter
provide important information concerning the propor-
tion of aberrant cells, while the genomic approaches are
based on cell averages. Therefore, quality control assess-
ment of hiPSC should first include a combination of
cytogenetic and genomic assays.
We expect in the future that assessing hiPSC quality
will incorporate assays that are based on single-cell gen-
omics and posttranscriptional modifications of pluripo-
tency genes and on methods that combine both. This is
because it is has been shown that iPSC exhibit unique
signatures of posttranscriptional modifications of mRNA,
especially at the 3′ UTR [69,70], and also because single-
cell genomics will provide information concerning the
proportion of normal/genetically aberrant cells [71]. In
addition, we expect that epigenetic analysis will become
common for evaluating hiPSC quality since it is likely that
some adult tissue DNA methylation markers, and possibly
histone markers, are maintained in iPSC [72].
Clinical application of iPSC
The future use of iPSC in the clinic largely relies on data
collected from past and current clinical trials using
hESC-derived cells [73,74].
iPSC to treat macular degeneration in humans
For hESC-RPE cells, there are currently two cell products
in clinical trials: Advanced Cell Technology (ACT) -
MA09-hRPE cells and Pfizer-UCL clinical trial - PF-
05206388 Living Tissue Equivalent. To date, Dr Masayo
Takahashi (Laboratory for Retinal Regeneration, RIKEN
Center for Developmental Biology) regulatory approval
has been in place since 2014 to conduct the first phase I
clinical trial using hiPSC-RPE in collaboration with the
Institute for Biomedical Research and Innovation and with
support from the Kobe City Medical Center General
Hospital.
The first human stem cell transplantation trial by ACT
used immunosuppression, and this is also planned for
the Pfizer London project trial. Stem cell sources for ret-
inal repair have been identified and validated including
human embryonic stem (hES) cells [5,28] (ACT and
Pfizer-UCL), induced pluripotent stem cells [75,76]
(RIKEN Center for Developmental Biology), retinal tissue
[77], umbilical tissue stem cells and retinal progenitor cells
[78,79]. Therefore, many groups have demonstrated suc-
cessful conversion of stem cells to human RPE or neuro-
retinal cells, particularly photoreceptors.
One of the primary outcomes of the hESC-RPE cell
suspension trial is ‘any evidence that the cells showing
tumorigenic potential’. Animal pre-clinical data showed
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100,000 RPE cells spiked with 1% undifferentiated hES
cells, and there was no tumour development after 4
months in human subjects who received the hESC-RPE
which had less than 1% residual undifferentiated hES
cells. It is reassuring that the potentially undifferentiated
hES cells injected into the subretinal space have not mi-
grated elsewhere in the eye, or systemically, causing
tumour formation. It is not certain whether the trans-
planted hESC-RPE survived the procedure in these pa-
tients since there were no data from in vivo imaging of
individual RPE cells.
An alternative to allogeneic sources of pre-made RPE
is patient-specific RPE derived from somatic cells, either
directly using defined RPE factors or via iPSC [80].
However, there are no data on the benefit of transplant-
ing these cells in animal models of retinal degeneration.
Autologous induced pluripotent stem cells have been
seen as advantageous as a source for retinal regeneration
because of the theoretical benefit of not needing im-
munosuppression and the ethical attraction of using
adult rather than embryonic tissue. In the RIKEN iPSC-
RPE trial, patients with wet AMD are recruited, but
there is a 10-month lag time between skin biopsy to har-
vest autologous cell source and shipment of iPSC-RPE
cell sheets for transplantation. However, there is little
published information of the technique of iPSC deriv-
ation and RPE characterisation for individual patients.
The estimated 10-month lag time and the USD 100,000
price tag for manufacturing the iPSC-RPE patch make
this technique more expensive than the alternative and
effective treatment in wet AMD such as ranibizumab or
aflibercept therapy.
Despite the enthusiasm for stem cell therapy, there re-
main a number of unaddressed, fundamental problems
in using allogeneic cells as a donor source in cell therapy
for AMD. The most important is immunological rejec-
tion. It is notable that the hES-RPE cell therapies being
pursued by pharmaceutical companies are based on sin-
gle hES cell lines with a propensity for spontaneous RPE
differentiation. However, such allogeneic hESC lines ne-
cessitate the use of immunosuppressive drugs to allow
the survival of foreign cells in the eye. It is also notable
that all previous attempts to correct AMD using allogen-
eic RPE cells (such as foetal or cadaveric RPE) failed due
to tissue rejection [81].
Although iPSC-derived RPE cell transplantation clin-
ical trials are underway in Japan, the iPSC were pro-
duced using non-clinical methods by retroviral or Sendai
virus induction and included the oncogene c-Myc in
the reprogramming factor cocktail [82]. While these
methods are useful for producing iPSC for research pur-
poses, we do not consider them appropriate for clinical
translation. The development of clinical-grade iPSC fortherapeutic applications such as the treatment of AMD
is an essential step that remains to be integrated into
iPSC-based cell therapy protocols and to receive appro-
priate regulatory approval.
Regulation of clinical trials
In any new area of translational science and potential
therapy, such as stem cell treatments, the initial steps
into human treatment are often the longest and hardest.
Part of the reason is that there is no framework or
experience in terms of guiding research direction.
Scientists, clinicians and regulators alike are entering
new and unfamiliar areas and, as such, progress ap-
pears slow. Regulation of hESC-derived stem cell tri-
als have been centred on safety and tumorigenicity
studies of the donor and derived cells. The advantage
of this approach is that it is finite with a single
source of cells and a potentially repeatable method
to produce RPE. Issues such as GMP standards for
RPE cells, clinical trial planning, critical areas of col-
laboration and clinical trial design have recently been
reviewed [83].
The UCL-Pfizer partnership undertaking the develop-
ment of hESC-RPE uses a polyester substrate carrier to
maintain polarity and differentiation of grafted cells. The
approval process for this cell-patch combination is more
complex than hESC-RPE cell suspension grafts since the
substrate, matrix coating and surgical delivery device all
require individual regulatory approval in addition to the
hESC-RPE cell product. Another major difference be-
tween the cell-patch trial and the RIKEN unsupported
RPE sheets trial is the patient inclusion criteria - the
UCL-Pfizer study will enrol patients with wet AMD ra-
ther than dry AMD. The purpose is to restore vision by
removing choroidal neovascularisation and restoring
submacular RPE to allow visual recovery, as opposed to
preventing further loss of vision in dry AMD, as is the
case for anti-VEGF treatments. Since the natural history
of untreated wet AMD is a rapid decline in vision, the
clinical effect will be apparent within 6 months, whereas
in the dry AMD trial, it may be many years or decades
before clinical benefit is apparent because of slow dis-
ease progression. In both hESC-RPE trials, immuno-
suppression is required due to the theoretical risk of
rejection.
Induced pluripotent cells from autologous donors
could present a regulatory challenge as each treatment
will be from a different donor and therefore represent a
different cell line. It will not be feasible to regulate each
cell line as a new entity due to time and resource rea-
sons, so there will need to be a dialogue between re-
searchers and regulators to resolve this. Initially, as more
information comes from the early hESC trials (ACT and
Pfizer-UCL) and retinal iPSC trial (RIKEN Center) there
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data that can be used to inform future regulation.
Clinical immunology of iPSC
The potential of iPSC to assist the regeneration, supple-
mentation or replacement of human tissues is currently
being realised through the evaluation of differentiated
tissues in small-animal models. For human clinical appli-
cations to be developed from this point, the following
immunological issues must be addressed.
Firstly, potential overexpression of proteins that are
not typically expressed in the target differentiated tissue
is a concern as this might introduce neo-antigens to
which the host might mount an immune response. Such
a scenario was reported by Zhao and colleagues [84]
who described the increased expression of a range of
gene products in teratomas derived from either lentiviral
vector- or episomal-driven iPSC of syngeneic murine
embryonic fibroblasts which were implanted subcutane-
ously. They further demonstrated that ectopic expres-
sion of some of these genes (Hormad1 and Zyg16) in
ESC lines could induce immunogenicity as indicated by
their failure to form teratomas after implantation in im-
munocompetent mice, with this immunity dependent on
both CD4+ and CD8+ T-cells. Of note, Hormad1 ex-
pression has been reported as a tumour antigen [85].
Two recent studies have separately tested the immuno-
genicity of iPSC-derived cells using quite different ap-
proaches. Araki et al. produced iPSC using lentiviral
vectors from either murine embryonic fibroblasts and
used these cells to create highly chimeric syngeneic
mice. Tissues such as the skin or bone marrow from
these chimeric mice were then grafted into syngeneic
hosts with no indications of immunity against the grafts
[86]. Guha et al., using tail tip fibroblasts, produced tis-
sues derived from three different embryonic germ layers
and implanted them under the kidney capsule. Again, no
evidence of graft-associated immunity could be detected
[87]. Interestingly, the study reported that embryoid
bodies (EB) derived from ESC, iPSC lines and the epi-
somal iPSC line, Epl, previously used by Zhao et al., all
expressed high levels of Hormad1, Zg16 and Retn, whilst
differentiated cells derived from each of these lines
did not.
Additional support for the successful use of iPSC as a
cell therapy has been shown in a study by Morizane and
colleagues where neuronal cells derived from human
leukocyte antigen (HLA)-matched non-human primate
iPSC, generated by both lentiviral and non-integrating
episomal methods, were successfully engrafted by injec-
tion into the brain of host monkeys, in the absence of
immunosuppression, and tolerated for greater than 3
months without signs of infiltration by MHC II+ host
microglia or CD3+ T-cells. Interestingly, neuronal graftsderived from HLA-mismatched donor cells, although in-
filtrated by microglia and CD3+ T-cells, also survived
beyond 3 months but at a lower number and density
[88]. Such recent results should provide encouragement
for additional studies using a wider range of iPSC differ-
entiated cell types in both murine and non-human pri-
mates and ultimately in clinical studies.
Secondly, the length of time necessary to achieve the
production of graft materials may be too long to be
practical, an issue that is directly related to the efficiency
of the iPSC process utilised. The methodology to gener-
ate iPSC is still under rapid and continual development,
with alternate delivery systems being evaluated, each
having potentially different immunogenic responses
[39,89]. We have recently reported on the development
of a novel culture environment, which includes the
addition of plant hormones such as auxin and cytokinin
to the retroviral infection cultures which resulted in a
twofold increase in the efficiency of iPSC development
and, in addition, showed the effect of downregulation of
the c-Myc oncogene [90]. Thus, we demonstrated that
plant hormones might have a role in increasing the effi-
cacy and safety of iPSC for cell replacement therapy. It
is critical to translate these recent developments to the
production of hiPSC so that they can be carefully char-
acterised with respect to that of non-immunogenic mur-
ine iPSC ahead of clinical trials.
Conclusions
The most exciting aspect in the field of iPSC technology
is the clinical application ongoing at RIKEN to treat
AMD with RPE cells. AMD is a unique disease to treat
with iPSC technology because the RPE cells used are ter-
minally differentiated, and the anatomical site of injec-
tion, the eye, is contained and easily recovered in case of
any side effects. For other diseases or conditions where
systemic cell therapy treatment is needed or the iPSC-
derived cells are still capable of proliferation or differen-
tiation, additional regulations will be needed. Cell
production issues such as genetic stability with expan-
sion in vitro, pluripotent capacity, homogenous popula-
tions will demand more in-depth analysis of iPSC than
the standard cytogenetic tests currently used. Regulatory
issues for clinical trials will have to be developed, includ-
ing comprehensive SOP for iPSC production, expansion,
differentiation and delivery. It will not be feasible to
regulate each cell line as a new entity due to time and
resource reasons, so there will need to be a dialogue be-
tween researchers and regulators to resolve this. There
needs to be careful consideration of the type of applica-
tion for which cells differentiated from iPSC will be
used. These issues may not be relevant for grafts that
augment or restore function, such as pancreatic beta cell
grafts to supplement insulin production or the grafting
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holy grail of accomplishing complete human organ re-
placement is still a high aspiration target of stem cell
biology, and this highlights an additional level of com-
plexity required in the coordinated differentiation and
integration of such with pre-existing host tissues. The
future looks bright and the whole world awaits the pio-
neering RIKEN trial for macular degeneration that will
point the way for treatment of other diseases or condi-
tions in the near future.
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